Pharmadrug Announces Closing of Sale of…
August 3, 2022
PharmaDrug Announces Non-Brokered Offering of $650,000…
August 2, 2022
PharmaDrug Announces Positive Findings for the…
June 16, 2022
PharmaDrug Announces Execution Of an Agreement…
May 31, 2022
PharmaDrug Announces Closing of the First…
May 27, 2022
Pharmadrug Advances Opthalmology Program with Final…
May 3, 2022
PharmaDrug Advances Oncology Program with Filing…
April 19, 2022
PharmaDrug Advances DMT-Analogue Program for Glaucoma…
April 7, 2022
Pharmadrug Advances PD-001, Its Patented, Improved…
April 1, 2022
PharmaDrug Announces Interim Positive Findings for…
March 9, 2022
PharmaDrug Receives Positive Results for DMT-Analogue…
February 23, 2022
PharmaDrug Announces Filing of US Provisional…
February 1, 2022
PharmaDrug Announces Initiation of Manufacturing of…
January 26, 2022
PharmaDrug to Present at Wall Street…
January 24, 2022
PharmaDrug Engages Octagon Media and Affiliated…
January 20, 2022
PharmaDrug Announces Resignation of Director
January 13, 2022
PharmaDrug Announces Addition of Dr. Cindy…
December 13, 2021
Pharmadrug Announces Successful Completion of Pre-IND…
November 30, 2021
PharmaDrug Provides Research Results and Initiates…
November 18, 2021
Study Results in the Prestigious Journal…
November 9, 2021
PharmaDrug Advances Psychedelics Program with Analogue…
November 5, 2021
PharmaDrug Expands Product Offering to Prepare…
November 1, 2021
PharmaDrug Commences Trading on the OTCQB…
October 20, 2021
PharmaDrug Announces Positive Research Results for…
October 15, 2021
PharmaDrug Announces pre-IND Meeting Request Granted…
September 28, 2021
PharmaDrug Announces Clinical Research Collaboration with…
August 25, 2021
PharmaDrug Forms Research Collaboration with Terasaki…
August 5, 2021
PharmaDrug Announces Stock Ticker Symbol Change…
July 30, 2021
Pharmadrug Announces Positive Research Results of…
July 28, 2021
